Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection

Peer Review reports

Original Submission
7 Jan 2021	Submitted	Original manuscript
21 Feb 2021	Author responded	Author comments - Masaaki Mori
Resubmission - Version 2
21 Feb 2021	Submitted	Manuscript version 2
Publishing
24 Feb 2021	Editorially accepted
2 Mar 2021	Article published	10.1186/s12887-021-02567-6

Back to article page